top of page
Therapeutic Development Pipeline
Aeterna is regaining rights to macimorelin (Macrilen™) in the United States and Canada in May 2023 and is engaged in robust business development efforts to identify and secure a new development and commercialization partner in these territories.
Specialty Biopharmaceutical Company
Data delayed 15 minutes unless otherwise indicated
bottom of page